Erythropoiesis-stimulating agents in anemia

T. S. Dharmarajan, David Widjaja

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Erythropoietin, a humoral factor produced predominantly in the kidney, stimulates red blood cell production in the bone marrow. Erythropoiesis- stimulating agents (ESAs) have been used for years in the treatment of anemia, with extensive experience and benefits in anemia of chronic kidney disease. Recent data have suggested adverse consequences with use of ESAs, perhaps relating to inappropriate use, and prompting release of guidelines to ensure safe use and maximize benefit. When prescribing ESAs, indications, requirements to monitor laboratory parameters (hemoglobin levels and ferrokinetics), and clinical status need to be stringently followed.

Original languageEnglish (US)
Pages (from-to)13-16+18+29
Issue number6
StatePublished - Jun 2008
Externally publishedYes


  • Anemia
  • Chronic kidney disease
  • Erythropoietin
  • Hemoglobin
  • Older adults

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Erythropoiesis-stimulating agents in anemia'. Together they form a unique fingerprint.

Cite this